Products for Research Use Only

Plerixafor

CAT: 0804-HY-10046-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10046-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM[1][2][3][4][7].
CAS Number
110078-46-1
Product Name Alternative
AMD 3100; JM3100; SID791
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CXCR; HIV
Type
Reference compound
Related Pathways
Anti-infection; GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection; Endocrinology; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Plerixafor.html
Purity
99.90
Solubility
DMSO : 1.92 mg/mL (ultrasonic; warming; adjust pH to 7 with 1 M HCl; heat to 60°C) |Ethanol : 50 mg/mL (ultrasonic)
Smiles
C1(CN2CCCNCCNCCCNCC2)=CC=C(C=C1)CN3CCNCCCNCCNCCC3
Molecular Formula
C28H54N8
Molecular Weight
502.78
Precautions
H302, H315, H319, H335
References & Citations
[1]Zabel BA, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009 Sep 1;183 (5) :3204-11.|[2]Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55.|[3]Yang J, et al. Continuous AMD3100 Treatment Worsens Renal Fibrosis through Regulation of Bone Marrow Derived Pro-Angiogenic Cells Homing and T-Cell-Related Inflammation. PLoS One. 2016 Feb 22;11 (2) :e0149926.|[4]Chu PY, et al. CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS One. 2015 Jul 27;10 (7) :e0133616.|[5]De Clercq E, et al. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619829382.|[6]Seki JT, et al. Chemical Stability of Plerixafor after Opening of Single-Use Vial. Can J Hosp Pharm. 2017 Jul-Aug;70 (4) :270-275.|[7]Schols D, et al. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res. 2006 Sep;71 (2-3) :216-26.|[8]Zheng J, et al. Toward Normalization of the Tumor Microenvironment for Cancer Therapy. Integr Cancer Ther. 2019;18:1534735419862352.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CXCR4; CXCR7; HIV-1; HIV-2
Citation 01
ACS Infect Dis. 2023 Nov 10;9 (11) :2105-2118.|Acta Biomater. 2024 Jul 17:S1742-7061 (24) 00395-7.|Acta Biomater. 2024 Mar 15:177:414-430.|Acta Pharmacol Sin. 2025 Oct 17.|Adv Funct Mater. 2024 Dec 23.|Adv Sci (Weinh) . 2025 Jun 19:e00225.|Andrology. 2023 Feb;11 (2) :295-306.|Bioact Mater. 2021 Jan 7;6 (7) :2039-2057.|Biochem Biophys Res Commun. 2021 Jan 1;534:337-342.|Biochem Pharmacol. 2025 Jun:236:116852.|Biomaterials. 2025 Jan 3:317:123091.|Biomed Pharmacother. 2020 Oct:130:110610.|Biomolecules. 2024 Sep 25;14 (10) :1206.|bioRxiv. 2025 Oct 7.|BMC Complement Altern Med. 2018 Dec 12;18 (1) :330. |Br J Haematol. 2023 May;201 (3) :459-469.|Cancer Lett. 2022 Oct 7;551:215944.|Cardiovasc Res. 2025 Nov 11:cvaf215.|Cell Death Dis. 2017 Jan 19;8 (1) :e2560. |Cell Death Dis. 2022 Feb 4;13 (2) :118.|Cell Death Dis. 2023 Mar 28;14 (3) :219.|Cell Death Discov. 2025 Apr 8;11 (1) :156.|Cell Mol Immunol. 2020 Mar;17 (3) :283-299.|Cell Mol Life Sci. 2024 Mar 13;81 (1) :132.|Cell Physiol Biochem. 2018;46 (3) :890-906. |Cell Rep Med. 2025 Jul 15;6 (7) :102211.|Cell Signal. 2020 Feb;66:109488.|Cell Tissue Res. 2020 Jun;380 (3) :469-486.|Cell Transplant. 2022 Jan-Dec;31:9636897221129171.|Cells. 2019 Jul 22;8 (7) :761.|Cells. 2022 Jan 4;11 (1) :155.|Chem Eng J. 2025 Oct 15.|Chinese Journal of Tissue Engineering Research . 2014,18 (45) : 7327-7332.|Drug Des Devel Ther. 2022 Jan 6;16:67-81.|Exp Ther Med. 2021 Sep;22 (3) :1037.|Fertil Steril. 2020 May;113 (5) :1067-1079.e5.|Immunity. 2024 Feb 13;57 (2) :364-378.e9.|Int Immunopharmacol. 2024 Nov 30:144:113707.|Int J Biol Sci. 2017 May 5;13 (5) :604-614.|Int J Mol Sci. 2023 Aug 13;24 (16) :12740.|Int J Mol Sci. 2024 Jul 1;25 (13) :7254.|Int J Mol Sci. 2024 May 4;25 (9) :5018.|Int J Nanomedicine. 2023 Jul 31:18:4329-4346.|Invest Ophthalmol Vis Sci. 2025 Aug 1;66 (11) :23.|J Cell Mol Med. 2025 Jan;29 (2) :e70352.|J Diabetes Complications. 2020 Oct;34 (10) :107654.|J Immunother Cancer. 2024 Dec 4;12 (12) :e009629.|J Mater Chem B. 2018 Apr 7;6 (13) :1951-1964.|J Nanobiotechnology. 2025 Aug 29;23 (1) :592.|J Oncol. 2021 Oct 8:2021:5584406.|J Periodontol. 2025 Jul 8.|J Steroid Biochem Mol Biol. 2021 Sep:212:105926.|J Transl Med. 2023 Sep 5;21 (1) :593.|Kaohsiung J Med Sci. 2022 Feb;38 (2) :120-128.|Leukemia. 2025 Aug 15.|Ludwig maxime clinic. University of Munich. 2019 Apr.|Mol Med Rep. 2020 Oct;22 (4) :3201-3212.|Nano Today. 2022, 47: 101689.|Nat Cell Biol. 2024 Aug;26 (8) :1346-1358.|Oncogene. 2019 Jun;38 (25) :5021-5037. |Oncol Lett. 2018 Sep;16 (3) :3976-3982. |Patent. US20200360478A1.|Phytomedicine. 2025 Jun:141:156667.|PLoS One. 2021 Mar 1;16 (3) :e0247707.|Res Sq. 2025 Aug 07.|Res Sq. 2025 Mar 16.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2022 Jul.|Research Square Preprint. 2023 Oct 23.|SSRN. 2025 Jan 13.|SSRN. 5 Feb 2022.|Stem Cell Res Ther. 2022 Feb 23;13 (1) :79.|Stem Cells Int. 2020 Jul 7;2020:1498315.|Theranostics. 2021 Jan 1;11 (6) :2612-2633.|Transl Stroke Res. 2022 Apr;13 (2) :276-286.|Universität Hamburg. Informatics and Natural Sciences. 2021 Mar 19.|University of Zagreb. 2024 May 23.|Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb.|Adv Funct Mater. 2020, 2000309.|Am J Physiol Cell Physiol. 2025 Apr 1;328 (4) :C1260-C1278.|Anticancer Drugs. 2017 Oct;28 (9) :935-942.|Brain Behav Immun. 2017 Jan:59:322-332.|J Neuroinflammation. 2025 Jun 28;22 (1) :169.|Mater Today Bio. 2024 Sep 1:28:101222.|Mol Ther-Nucl Acids. 2023 Mar 9.|Oncogene. 2022 Oct;41 (41) :4633-4644.|Oxid Med Cell Longev. 2021 Aug 2;2021:9993240.|Patent. US20190133998A1.|Pharmaceutics. 2021 Mar 24;13 (4) :439.|Proc Natl Acad Sci U S A. 2025 Mar 18;122 (11) :e2425795122.|Ruprecht-Karls-University Heidelberg. 2023 Aug 3.

Chemical Information

Plerixafor

Plerixafor is an azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. It has a role as a C-X-C chemokine receptor type 4 antagonist, an antineoplastic agent, an immunological adjuvant and an anti-HIV agent. It is a member of benzenes, a crown amine, an azacycloalkane, a secondary amino compound, a tertiary amino compound and an azamacrocycle. It is functionally related to a 1,4,8,11-tetraazacyclotetradecane.

CAS Number110078-46-1
PubChem CID65015
IUPAC Name1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
Molecular FormulaC28H54N8
Molecular Weight502.8
XLogP0
Topological Polar Surface Area78.7
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Heavy Atom Count36
Formal Charge0
Complexity456
SMILES
C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
InChI
InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
InChIKey
YIQPUIGJQJDJOS-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Plerixafor
CAS: 110078-46-1
CID: 65015
Formula: C28H54N8
MW: 502.8
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight502.8
XLogP30
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Exact Mass502.44714376
Monoisotopic Mass502.44714376
Topological Polar Surface Area78.7 Ų
Heavy Atom Count36
Formal Charge0
Complexity456
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Popular Products